The CEO of Dr. Reddy's Laboratories, a major Indian pharmaceutical company, has warned that proposed U.S. tariffs on generic drugs could lead to higher prices for patients. The company's chief executive said that if the Trump administration imposes tariffs on imported generic medicines, the additional costs would likely be passed on to American consumers. Generic drugs are typically cheaper alternatives to brand-name medications and are widely used in the United States to keep healthcare costs down. India is one of the largest suppliers of generic drugs to the U.S. market. The CEO's comments come amid ongoing trade tensions and discussions about increasing tariffs on various imported goods. The warning highlights potential consequences for healthcare affordability if tariffs are applied to pharmaceutical imports. The U.S. government has not yet announced specific tariff rates on generic drugs, but the prospect has raised concerns among industry leaders and patient advocacy groups. Higher prices could strain patients who rely on affordable medications to manage chronic conditions. The CEO urged policymakers to consider the impact on public health before implementing such measures. The situation remains under review as trade negotiations continue.